Robert V.  Baumgartner net worth and biography

Robert Baumgartner Biography and Net Worth

Director of Bio-Techne
Mr. Baumgartner has served on the Company's Board since 2003 and as Chairman since 2012. Until July of 2019, Mr. Baumgartner served as Executive Chairman, Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers. Until August, 2015, Mr. Baumgartner also served as Chief Executive Officer of that company. Prior to 2001, he held numerous executive positions, including as Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar and President of the Apogee Glass Group. He began his professional career at KPMG LLC, an international accounting firm. Mr. Baumgartner currently serves on the board of Carestream Health, Inc.

What is Robert V. Baumgartner's net worth?

The estimated net worth of Robert V. Baumgartner is at least $720,355.68 as of May 10th, 2022. Baumgartner owns 10,106 shares of Bio-Techne stock worth more than $720,356 as of November 23rd. This net worth approximation does not reflect any other assets that Baumgartner may own. Learn More about Robert V. Baumgartner's net worth.

How do I contact Robert V. Baumgartner?

The corporate mailing address for Baumgartner and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on Robert V. Baumgartner's contact information.

Has Robert V. Baumgartner been buying or selling shares of Bio-Techne?

Robert V. Baumgartner has not been actively trading shares of Bio-Techne during the past quarter. Most recently, on Tuesday, May 10th, Robert V. Baumgartner bought 300 shares of Bio-Techne stock. The stock was acquired at an average cost of $352.55 per share, with a total value of $105,765.00. Following the completion of the transaction, the director now directly owns 10,106 shares of the company's stock, valued at $3,562,870.30. Learn More on Robert V. Baumgartner's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (CEO, President & Director), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 10,400 shares worth more than $800,592.00. The most recent insider tranaction occured on March, 7th when Director Roeland Nusse sold 10,400 shares worth more than $800,592.00. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 3/7/2024.

Robert V. Baumgartner Insider Trading History at Bio-Techne

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2022Buy300$352.55$105,765.0010,106View SEC Filing Icon  
5/21/2020Sell5,000$266.42$1,332,100.0014,221View SEC Filing Icon  
8/7/2019Buy500$191.06$95,530.008,726View SEC Filing Icon  
11/1/2017Sell5,000$130.18$650,900.0012,712View SEC Filing Icon  
9/2/2016Sell6,467$107.17$693,068.398,446View SEC Filing Icon  
8/24/2016Sell3,533$107.10$378,384.309,592View SEC Filing Icon  
See Full Table

Robert V. Baumgartner Buying and Selling Activity at Bio-Techne

This chart shows Robert V Baumgartner's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $71.28
Low: $70.61
High: $72.41

50 Day Range

MA: $73.77
Low: $66.37
High: $80.36

2 Week Range

Now: $71.28
Low: $61.16
High: $85.57

Volume

620,615 shs

Average Volume

1,229,735 shs

Market Capitalization

$11.33 billion

P/E Ratio

75.83

Dividend Yield

0.45%

Beta

1.28